Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset
Chandler M, Recht M, He C, Moulton T, Charafi L. Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset. Blood 2021, 138: 4241. DOI: 10.1182/blood-2021-152345.Peer-Reviewed Original ResearchDamoctocog alfa pegolHemophilia treatment centersAdolescent patientsBleeding rateTreated twice-weeklyHistory of inhibitorsYear of therapyAmerican ThrombosisAge of patientsMonths of treatmentSevere hemophilia ASubgroup of patientsHemophilia A patientsProportion of patientsBaseline demographic dataPatient chart reviewReal-world studyHemostasis NetworkData cutoffA patientsBleeding eventsWeekly dosesHemophilia AChart reviewOregon Health & Science University
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply